Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery
- 12 July 2017
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (30) , E6231-E6239
Abstract
Inadequate target exposure is a major cause of high attrition in drug discovery. Here, we show that a label-free method for quantifying the intracellular bioavailability (Fic) of drug molecules predicts drug access to intracellular targets and hence, pharmacological effect. We determined Fic in multiple cellular assays and cell types representing different targets from a number of therapeutic areas, including cancer, inflammation, and dementia. Both cytosolic targets and targets localized in subcellular compartments were investigated. Fic gives insights on membrane-permeable compounds in terms of cellular potency and intracellular target engagement, compared with biochemical potency measurements alone. Knowledge of the amount of drug that is locally available to bind intracellular targets provides a powerful tool for compound selection in early drug discovery. Significance Exposure at the site of action has been identified as one of the three most important factors for success in drug discovery and the design of chemical probes. Modern drug discovery programs have, to a great extent, shifted to intracellular targets, but methods to determine intracellular drug concentrations have been lacking. Here, we use a methodology for predicting intracellular exposure of small-molecule drugs to understand their potency toward intracellular targets. We show that our approach is generally applicable to multiple targets, cell types, and therapeutic areas. We expect that routine measurements of intracellular drug concentration will contribute to reducing the high attrition observed in drug discovery and the design of both better chemical probes and medicines.Keywords
Funding Information
- Vetenskapsrådet (2822)
- Ministry of Education and Science | Fundação para a Ciência e a Tecnologia (SFRH/BD/68304/2010)
This publication has 70 references indexed in Scilit:
- The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaquesActa Neuropathologica, 2013
- Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug InteractionsJournal of Medicinal Chemistry, 2012
- Cationic Amphiphilic Drugs Cause a Marked Expansion of Apparent Lysosomal Volume: Implications for an Intracellular Distribution-Based Drug InteractionMolecular Pharmaceutics, 2012
- In-cell click labelling of small molecules to determine subcellular localisationJournal of Chemical Biology, 2010
- Subcellular targeting strategies for drug design and deliveryNature Reviews Drug Discovery, 2010
- Target identification using drug affinity responsive target stability (DARTS)Proceedings of the National Academy of Sciences of the United States of America, 2009
- The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic PotentialThe Journal of Neuroscience, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006